Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT06331312
Registration number
NCT06331312
Ethics application status
Date submitted
20/03/2024
Date registered
26/03/2024
Date last updated
16/04/2024
Titles & IDs
Public title
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Query!
Scientific title
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR)
Query!
Secondary ID [1]
0
0
2023-508077-85-00
Query!
Secondary ID [2]
0
0
CAIN457C22301E1
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REPLENISH-EXT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Polymyalgia Rheumatica
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Secukinumab
Experimental: Secukinumab 300mg - All eligible participants will receive secukinumab 300 mg s.c. (2 x 150mg/1mL PFS secukinumab) from baseline and every 4 weeks up to 2 years. The study medication may be modified/adjusted after the initial doses of 300mg s.c. (decreased to 150mg s.c. q4w or increased again from 150mg s.c. q4w to 300mg s.c. q4w) if deemed appropriate by the investigator. Dose modification/adjustment may only occur from Week 24 visit onwards. The modification/adjustment of the study medication will be determined at a site visit.
Other interventions: Secukinumab
2 x 150mg/1mL PFS secukinumab
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidences of treatment emergent adverse events (AEs) and serious adverse events (SAEs)
Query!
Assessment method [1]
0
0
The number and percentage of participants with treatment emergent AEs/SAEs will be summarized. No hypothesis testing will be performed.
Query!
Timepoint [1]
0
0
After the first dose of study treatment and within 84 days after the last dose
Query!
Eligibility
Key inclusion criteria
- Participants who have completed 52-week Treatment Period as per protocol in a Novartis
study of secukinumab in PMR patients (the "core study" - Study CAIN457C22301), AND
- who have experienced a relapse during the treatment-free follow-up period of the
core study, AND
- who have not been on rescue treatment.
- The participant would potentially derive benefit from secukinumab, and the benefit
outweighs the risk, based on the investigator's judgement.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Use of prohibited medications, as specified in the protocol
- History of ongoing, chronic or recurrent infectious disease (i.e., human
immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), active
tuberculosis infection (TB))
- History of lymphoproliferative disease or any known malignancy or history of
malignancy of any organ system within the past 5 years (except for basal cell
carcinoma or actinic keratosis that have been treated with no evidence of recurrence
in the past 3 months carcinoma in situ of the cervix or non-invasive malignant colon
polyps that have been removed).
- Live vaccinations (e.g., monkey pox vaccine, oral polio vaccine, varicella/zoster
vaccines) within 6 weeks prior to Baseline
- Subjects whose participation in the extension study could expose them to an undue
safety risk
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
10/04/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
8/05/2028
Query!
Actual
Query!
Sample size
Target
300
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Parramatta
Query!
Recruitment postcode(s) [1]
0
0
2150 - Parramatta
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this extension study is to assess the safety and tolerability of secukinumab
when administered long-term in patients with polymyalgia rheumatica.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT06331312
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-888-669-6682
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT06331312
Download to PDF